{"issuance_frequency":"","notes_translated":{"fr":"La présente ligne directrice s'adresse aux promoteurs qui ont l'intention d'apporter des changements aux drogues nouvelles pour lesquelles un AC a été délivré aux termes de l'article C.08.004 du Règlement sur les aliments et drogues. Ces nouvelles drogues peuvent être des produits pharmaceutiques, biologiques et radiopharmaceutiques à usage humain de même, incluant les présentations pour lesquelles un AC a été recommandé, mais dont la délivrance a été suspendue.","en":"This guidance document applies to sponsors intending to make changes to new drugs that have received a NOC pursuant to section C.08.004 of the Food and Drug Regulations. These new drugs may include pharmaceuticals, biologics, and radiopharmaceuticals for human use, including those submissions for which a NOC has been recommended but issuance of the NOC has been placed on hold."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"6230a286-505e-4bf9-ba05-09eff83911c4","metadata_created":"2021-07-07T19:51:38.966592","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-07T19:51:38.966599","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-07","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Document d'orientation","post-avis de conformité","changements d'AC","changements aux nouveaux médicaments","document d'innocuité et d'efficacité","produits pharmaceutiques","biologiques","radiopharmaceutiques","médicaments à usage humain","article C.08.004 du Règlement sur les aliments et drogues"],"en":["Guidance document","post-notice of compliance","NOC Changes","changes to new drugs","safety and efficacy document","pharmaceutical","biologic","radiopharmaceutical","drugs for human use","section C.08.004 of the Food and Drug Regulations"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice : Changements survenus après l’avis de conformité (AC) : Document sur l’innocuité et l’efficacité (Pour les produits biologiques, pharmaceutiques et radiopharmaceutiques à usage humain seulement)","en":"Guidance Document: Post-Notice of Compliance (NOC) Changes: Safety and Efficacy Document (for pharmaceutical, biologic and radiopharmaceutical drugs for human use only)"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"6230a286-505e-4bf9-ba05-09eff83911c4","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"4cf8d114-aa17-4c7b-a446-4813c55cbef2","related_relationship":"","name_translated":{"fr":"Ligne directrice : Changements survenus après l’avis de conformité (AC) : Document sur l’innocuité et l’efficacité (Pour les produits biologiques, pharmaceutiques et radiopharmaceutiques à usage humain seulement)","en":"Guidance Document: Post-Notice of Compliance (NOC) Changes: Safety and Efficacy Document (for pharmaceutical, biologic and radiopharmaceutical drugs for human use only)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Post-Notice of Compliance (NOC) Changes: Safety and Efficacy Document (for pharmaceutical, biologic and radiopharmaceutical drugs for human use only)","language":["en"],"created":"2021-07-07T19:51:39.074240","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/post-notice-compliance-changes/safety-efficacy-2019/document.html#a1","last_modified":null,"position":0,"revision_id":"e8d5829c-5a52-4f28-a8d4-1ab77c303cc0","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"6230a286-505e-4bf9-ba05-09eff83911c4","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"6b4cee03-f101-4396-a1ba-206fcec9aa51","related_relationship":"","name_translated":{"fr":"Ligne directrice : Changements survenus après l’avis de conformité (AC) : Document sur l’innocuité et l’efficacité (Pour les produits biologiques, pharmaceutiques et radiopharmaceutiques à usage humain seulement)","en":"Guidance Document: Post-Notice of Compliance (NOC) Changes: Safety and Efficacy Document (for pharmaceutical, biologic and radiopharmaceutical drugs for human use only)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Post-Notice of Compliance (NOC) Changes: Safety and Efficacy Document (for pharmaceutical, biologic and radiopharmaceutical drugs for human use only)","language":["fr"],"created":"2021-07-07T19:51:39.074246","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/changements-survenus-apres-avis-conformite/innocuite-efficacite-2019/document.html#a11","last_modified":null,"position":1,"revision_id":"e8d5829c-5a52-4f28-a8d4-1ab77c303cc0","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2020-04-01 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"6230a286-505e-4bf9-ba05-09eff83911c4","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"This guidance document applies to sponsors intending to make changes to new drugs that have received a NOC pursuant to section C.08.004 of the Food and Drug Regulations. These new drugs may include pharmaceuticals, biologics, and radiopharmaceuticals for human use, including those submissions for which a NOC has been recommended but issuance of the NOC has been placed on hold.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document: Post-Notice of Compliance (NOC) Changes: Safety and Efficacy Document (for pharmaceutical, biologic and radiopharmaceutical drugs for human use only)","revision_id":"e8d5829c-5a52-4f28-a8d4-1ab77c303cc0"}